4

OWNERSHIP DOCUMENT

Company: Protalix BioTherapeutics, Inc.
Filed: February 28, 2022
Period of Report: February 25, 2022
Accession Number: 0001104659-22-028157

View Document ↗ View on SEC.gov ↗